A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

NCT04964089 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

557

Enrollment

INDUSTRY

Sponsor class

Conditions

Wet Age-related Macular Degeneration

Interventions

DRUG: KSI-301
DRUG: Aflibercept
OTHER: Sham Procedure

Sponsor

Kodiak Sciences Inc